Protara Therapeutics, Inc. (TARA)
3.94
+0.04
(+1.03%)
USD |
NASDAQ |
Sep 02, 16:00
3.945
0.00 (0.00%)
After-Hours: 20:00
Protara Therapeutics Research and Development Expense (Annual) : 42.49M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 42.49M |
| December 31, 2024 | 31.57M |
| December 31, 2023 | 24.78M |
| December 31, 2022 | 16.67M |
| December 31, 2021 | 21.05M |
| December 31, 2020 | 11.88M |
| December 31, 2019 | 3.862M |
| Date | Value |
|---|---|
| December 31, 2018 | 11.85M |
| December 31, 2017 | 21.69M |
| December 31, 2016 | 18.87M |
| December 31, 2015 | 12.38M |
| December 31, 2014 | 6.432M |
| December 31, 2013 | 3.994M |
| December 31, 2012 | 5.907M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 3.976M |
| Summit Therapeutics, Inc. | 537.67M |
| Kezar Life Sciences, Inc. | 33.76M |
| Clene, Inc. | 12.66M |